Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Next-generation sequencing reveals clinically actionable molecular markers in myeloid sarcoma

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937–951.

    Article  CAS  Google Scholar 

  2. Ansari-Lari MA, Yang CF, Tinawi-Aljundi R, Cooper L, Long P, Allan RH et al. FLT3 mutations in myeloid sarcoma. Br J Haematol 2004; 126: 785–791.

    Article  CAS  Google Scholar 

  3. Falini B, Lenze D, Hasserjian R, Coupland S, Jaehne D, Soupir C et al. Cytoplasmic mutated nucleophosmin (NPM) defines the molecular status of a significant fraction of myeloid sarcomas. Leukemia 2007; 21: 1566–1570.

    Article  CAS  Google Scholar 

  4. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 2004; 91: 355–358.

    Article  CAS  PubMed Central  Google Scholar 

  5. Rollig C, Bornhauser M, Thiede C, Taube F, Kramer M, Mohr B et al. Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system. J Clin Oncol 2011; 29: 2758–2765.

    Article  Google Scholar 

  6. Dufresne A, Bertucci F, Penel N, Le Cesne A, Bui B, Tubiana-Hulin M et al. Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis. Br J Cancer 2010; 103: 482–485.

    Article  CAS  PubMed Central  Google Scholar 

  7. Saini M, Jha AN, Abrari A, Ali S . Expression of proto-oncogene KIT is up-regulated in subset of human meningiomas. BMC Cancer 2012; 12: 212.

    Article  CAS  PubMed Central  Google Scholar 

  8. Inokuchi K, Yamaguchi H, Tarusawa M, Futaki M, Hanawa H, Tanosaki S et al. Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia—potential clinical significance. Leukemia 2002; 16: 170–177.

    Article  CAS  Google Scholar 

  9. Foster R, Byrnes E, Meldrum C, Griffith R, Ross G, Upjohn E et al. Association of paediatric mastocytosis with a polymorphism resulting in an amino acid substitution (M541L) in the transmembrane domain of c-KIT. Br J Dermatol 2008; 159: 1160–1169.

    CAS  PubMed  Google Scholar 

  10. Shih AH, Abdel-Wahab O, Patel JP, Levine RL . The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 2012; 12: 599–612.

    Article  CAS  Google Scholar 

  11. Braggio E, Egan JB, Fonseca R, Stewart AK . Lessons from next-generation sequencing analysis in hematological malignancies. Blood Cancer J 2013; 3: e127.

    Article  CAS  PubMed Central  Google Scholar 

  12. Cancer Genome Atlas Research N. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059–2074.

    Article  Google Scholar 

  13. Gaidzik VI, Schlenk RF, Moschny S, Becker A, Bullinger L, Corbacioglu A et al. Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. Blood 2009; 113: 4505–4511.

    Article  CAS  PubMed Central  Google Scholar 

  14. Casalegno-Garduno R, Schmitt A, Schmitt M . Clinical peptide vaccination trials for leukemia patients. Expert Rev Vaccines 2011; 10: 785–799.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was funded by the American Cancer Society Institutional Research Grant (#IRG-58-004) and the University of Chicago Comprehensive Cancer Center Support Grant (#P30 CA14599).

Author Contributions

ZL, MS, MKM, KLY and OB performed the experiments. FS, RL, WS and KO contributed patient samples and clinical data. ZL, MS, FS, KO, LJ and GR analyzed and interpreted the data. ZL, FS, KO and GR wrote the paper. GR designed and coordinated the research study.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to G Raca.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, Z., Stölzel, F., Onel, K. et al. Next-generation sequencing reveals clinically actionable molecular markers in myeloid sarcoma. Leukemia 29, 2113–2116 (2015). https://doi.org/10.1038/leu.2015.81

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2015.81

This article is cited by

Search

Quick links